The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-10), Alk-Abello AS's 14-Day RSI is 60.67.
The industry rank for Alk-Abello AS's 14-Day RSI or its related term are showing as below:
CHIX:ALKBc's 14-Day RSI is ranked better than 82.11% of 1420
companies
in the Biotechnology industry
Industry Median: 48.885
vs CHIX:ALKBc: 60.67
Alk-Abello AS (CHIX:ALKBc) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Alk-Abello AS 14-Day RSI Related Terms
CHIX:ALKBC vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Alk-Abello AS's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS (CHIX:ALKBC) has a 14-Day RSI of 60.67 as of Jul. 10, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Alk-Abello AS and its competitors. According to the industry distribution chart, Alk-Abello AS ranks #254 out of 1420 companies in the Biotechnology industry, placing it in the top 17.9%.
Is Alk-Abello AS's 14-Day RSI too high?
Alk-Abello AS's current 14-Day RSI is 60.67. The Biotechnology industry median 14-Day RSI is 48.89. Alk-Abello AS's value of 60.67 is 24.1% above this industry median. Based on the distribution chart, Alk-Abello AS ranks #254 out of 1420 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alk-Abello AS has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #254 out of 1420 companies for 14-Day RSI. This places Alk-Abello AS in the top 18% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 48.89. Alk-Abello AS's value of 60.67 is 24.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.89, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current 14-Day RSI of 60.67 is 24.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Alk-Abello AS and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current 14-Day RSI is 60.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr207.86, compared to a current price of kr256.30 — trading 23.3% above its estimated fair value. The current 14-Day RSI is 60.67 and 24.1% above the Biotechnology industry median of 48.89. Alk-Abello AS's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current 14-Day RSI is 60.67 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of kr256.30 is trading 23.3% above its estimated GF Value™ of kr207.86.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for CHIX:ALKBC:
14-Day RSI: 60.67
GF Value™: kr207.86 vs. price of kr256.30 (23.3% above fair value)
Industry Position: 24.1% above the Biotechnology median (#254 of 1420)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
92GF Score
Get the complete analysis for CHIX:ALKBC
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 